CA 125 Test Market Research Report - Forecast Till 2030

CA 125 Test Market Information: By Devices (Spectrometer, Analyzer, Sample Collection Tube, Otopic Labeled Peptides), Indication (Cancer, Uterine Fibroid, Endometriosis), End User (Hospitals & Clinics, Diagnostic Centers) - Forecast till 2030

ID: MRFR/LS/3526-HCR | December 2022 | Region: Global | 110 Pages         

CA 125 Test Market Speak to Analyst Request a Free Sample

CA 125 Test Market Overview


The CA 125 test market is projected to reach USD 1091.7 Million by 2030 at 5.80% CAGR during the forecast period 2022-2030. The Cancer Antigen (CA) test is used to identify cancer, uterine fibroids, endometriosis, and liver illness, among other diseases. The protein CA 125 was discovered in the blood. The test is most commonly used in women to diagnose ovarian cancer. CA 125 levels in the blood should be less than 30 units per mL, and increased CA 125 levels indicate the existence of ovarian cancer. In addition to diagnosis, the CA 125 test is used to monitor ovarian cancer and to screen for ovarian cancer in women who are suspected of having the illness.


There is increasing demand for cancer diagnostic and treatment services, an increased prevalence of cancer among women, and an increasing emphasis on women's healthcare. Furthermore, the expansion of the CA 125 test market is fueled by widespread cancer diagnostic testing. The high cost of instruments used in cancer diagnostics is limiting the expansion of the CA 125 test market.


FIGURE 1: Global CA 125 test Market by Type, 2016 (%)
CA 125 Test Market
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation 


Intended Audience



  • Medical Device Manufacturers

  • Medical Device Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Segments 


The CA 125 test market is segmented on the basis of devices and accessories, devices, and end user.


On the basis of devices and accessories, CA 125 test market is segmented into spectrometer, analyzer, sample collection tubes, isotopic labeled peptides, and others.


On the basis of indication, the CA 125 test market is segmented into cancer, uterine fibroids, endometriosis, liver diseases, and others. Cancer is further segmented into ovarian cancer, endometrial cancer, fallopian tube cancer, stomach cancer, breast cancer, and others.


On the basis of end user, the CA 125 test market is segmented into hospitals & clinics, diagnostic centers, and others.

Key Players in the Global CA 125 Test Market 


Some of the key players in CA 125 test market are Allergan plc. (U.K), Amgen Inc. (U.S.), Bayer (Germany), BD (U.S.), Eli Lilly Company (U.S.) , Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Private Limited (Israel), AMAG Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Sanofi (France), Novartis (Germany), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (U.S.), and others.


Research Methodology


Global CA 125 Test Market
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation

Recent Development


Merck & Co., Inc. (Merck) is a biopharmaceutical firm that develops, manufactures, and markets prescription drugs, biologic treatments, vaccines, and animal health products. It offers prescription medications for therapeutic areas linked to cardiovascular disease, cancer, immunological disorders, infectious, respiratory, and women's illnesses, and diabetes. The corporation operates throughout the Americas, Europe, the Middle East, Africa, Asia-Pacific, and Latin America through its subsidiaries. Merck is based in Kenilworth, New Jersey, and is known as MSD outside of the United States and Canada.


One corporation that is leading the way is Novartis. They are not just one of the world's largest pharmaceutical corporations, but they are also pursuing an unconventional strategy. To be sure, the pharmaceutical sector is closely examined by the general public and government organizations. Novartis has opted to focus on establishing public confidence through industry-leading ethical standards and efforts to improve the world.


Regional Analysis of the CA 125 Test Market                


America holds the first position in the CA 125 test market owing to the rising prevalence of ovarian cancer in the U.S. and Canada. Additionally, the availability of a wide range of diagnosis and treatment methods for cancer and technological advancement in the field of oncology, also support the growth of the market in American countries. Presence of key player in the market also accelerates the growth of the CA 125 test market. These players are engaged in various strategic approaches such as mergers, acquisition, collaborations, partnership, and research activities, leading to the development of the market in North America.


In Europe, the market shows extensive growth owing to extensive research and development activities, and increasing demand for new medical devices for diagnosis of cancer drive the growth of the CA 125 test market. Germany, U.K, and France acquire first, second and third place respectively, in the European CA 125 test market.


The market in Asia Pacific is expected to grow at the fastest pace whose market is driven rising awareness about reproductive health and diseases among women, and improving healthcare infrastructure. Availability of highly qualified healthcare professionals such as physicians, surgeons and gynecologist in the developing regions such as India, Japan and China further fuel the CA 125 test market.


The Middle East & Africa also show a steady rise in the market owing to low prevalence of ovarian cancer, rising demand for diagnostic services and growing emphasis on diagnosis and treatment of cancer disease. Developing healthcare infrastructure in the Middle East also fuels the growth of the CA 125 test market. In the Middle East & Africa, the Middle East accounts for the largest market share owing to the availability of better healthcare services in the Middle East countries than in Africa.



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 1091.7 Million
  CAGR   5.40%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Devices and Accessories, Devices, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Allergan plc. (U.K), Amgen Inc. (U.S.), Bayer (Germany), BD (U.S.), Eli Lilly Company (U.S.) , Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Private Limited (Israel), AMAG Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Sanofi (France), Novartis (Germany), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (U.S.), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing demand for cancer diagnosis and treatment services
  • Rising prevalence of cancer
  • Increasing emphasis on women healthcare


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    CA 125 test market CAGR 5.40% during the forecast period.

    CA 125 test market would get boosted by growing demand for cancer diagnosis.

    The devices and accessories mentioned in the CA 125 test market are analyzer, spectrometer, isotopic labeled peptides, sample collection tubes, and others.

    CA 125 test market players are Bayer (Germany), Allergan plc. (U.K), Amgen Inc. (U.S.), Merck & Co., Inc. (U.S.), BD (U.S.), Eli Lilly Company (U.S.), Teva Pharmaceuticals Private Limited (Israel), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Sanofi (France), AMAG Pharmaceuticals (U.S.), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (U.S.), Novartis (Germany), and others.

    The Americas would take charge of the CA 125 test market.